Thomas Ebert1,2, Nicolas Linder3,4, Alexander Schaudinn4, Harald Busse4, Joachim Berger5, Ralf Lichtinghagen6, Volker Keim5, Johannes Wiegand5, Thomas Karlas5. 1. Department of Endocrinology and Nephrology, University of Leipzig, 04103, Leipzig, Germany. Thomas.ebert@medizin.uni-leipzig.de. 2. Leipzig University Medical Center, IFB AdiposityDiseases, 04103, Leipzig, Germany. Thomas.ebert@medizin.uni-leipzig.de. 3. Leipzig University Medical Center, IFB AdiposityDiseases, 04103, Leipzig, Germany. 4. Department of Diagnostic and Interventional Radiology, University Hospital Leipzig, 04103, Leipzig, Germany. 5. Division of Gastroenterology and Rheumatology, University Hospital Leipzig, 04103, Leipzig, Germany. 6. Institute of Clinical Chemistry, Hannover Medical School, 30625, Hannover, Germany.
Abstract
OBJECTIVE: The liver-derived plasma protein fetuin B is associated with nonalcoholic fatty liver disease (NAFLD) and impaired glucose homeostasis in mice. However, its association with non-invasive ultrasound- and magnetic resonance (MR)-based markers of liver fibrosis and steatosis, the enhanced liver fibrosis (ELF) score, liver biopsy, as well as rs738409 in PNPLA3, has not been elucidated in NAFLD, so far. DESIGN AND METHODS: The association of circulating fetuin B and transient elastography (TE), controlled attenuation parameter (CAP), 1H-MR-spectroscopy, the ELF score, liver biopsy, as well as risk alleles in rs738409 in PNPLA3, was studied in 101 NAFLD patients as compared to 15 healthy controls. RESULTS: Serum fetuin B levels did not differ between NAFLD patients and controls (p = 0.863). Fetuin B was independently and negatively associated with transient elastography liver stiffness measurement (LSM) (p = 0.002), but not with the steatosis markers CAP or 1H-MR-spectroscopy. Fetuin B serum concentrations were significantly lower in individuals with LSM > 7.0 kPa as compared to patients with LSM < 7.0 kPa (p = 0.024). Furthermore, the ELF score and histologically proven fibrosis were independent and negative predictors of circulating fetuin B. Moreover, serum fetuin B significantly depended on number of rs738409 risk alleles (p = 0.026). CONCLUSIONS: Fetuin B is independently and negatively associated with non-invasive markers of liver fibrosis and PNPLA3 status in NAFLD patients but does not show a correlation with the hepatic lipid content. Future studies need to elucidate the pathophysiological significance of fetuin B in NAFLD and its potential value as predictor for disease severity.
OBJECTIVE: The liver-derived plasma protein fetuin B is associated with nonalcoholic fatty liver disease (NAFLD) and impaired glucose homeostasis in mice. However, its association with non-invasive ultrasound- and magnetic resonance (MR)-based markers of liver fibrosis and steatosis, the enhanced liver fibrosis (ELF) score, liver biopsy, as well as rs738409 in PNPLA3, has not been elucidated in NAFLD, so far. DESIGN AND METHODS: The association of circulating fetuin B and transient elastography (TE), controlled attenuation parameter (CAP), 1H-MR-spectroscopy, the ELF score, liver biopsy, as well as risk alleles in rs738409 in PNPLA3, was studied in 101 NAFLD patients as compared to 15 healthy controls. RESULTS: Serum fetuin B levels did not differ between NAFLD patients and controls (p = 0.863). Fetuin B was independently and negatively associated with transient elastography liver stiffness measurement (LSM) (p = 0.002), but not with the steatosis markers CAP or 1H-MR-spectroscopy. Fetuin B serum concentrations were significantly lower in individuals with LSM > 7.0 kPa as compared to patients with LSM < 7.0 kPa (p = 0.024). Furthermore, the ELF score and histologically proven fibrosis were independent and negative predictors of circulating fetuin B. Moreover, serum fetuin B significantly depended on number of rs738409 risk alleles (p = 0.026). CONCLUSIONS:Fetuin B is independently and negatively associated with non-invasive markers of liver fibrosis and PNPLA3 status in NAFLD patients but does not show a correlation with the hepatic lipid content. Future studies need to elucidate the pathophysiological significance of fetuin B in NAFLD and its potential value as predictor for disease severity.
Authors: S Kralisch; A Hoffmann; N Klöting; A Bachmann; J Kratzsch; M Blüher; M-Z Zhang; R C Harris; M Stumvoll; M Fasshauer; T Ebert Journal: Diabetes Metab Date: 2017-02-14 Impact factor: 6.041
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day Journal: Hepatology Date: 2007-04 Impact factor: 17.425
Authors: Thomas Karlas; David Petroff; Nikita Garnov; Stephan Böhm; Hannelore Tenckhoff; Christian Wittekind; Manfred Wiese; Ingolf Schiefke; Nicolas Linder; Alexander Schaudinn; Harald Busse; Thomas Kahn; Joachim Mössner; Thomas Berg; Michael Tröltzsch; Volker Keim; Johannes Wiegand Journal: PLoS One Date: 2014-03-17 Impact factor: 3.240
Authors: Xiongfeng Pan; Atipatsa C Kaminga; Jihua Chen; Miyang Luo; Jiayou Luo Journal: Int J Environ Res Public Health Date: 2020-04-15 Impact factor: 3.390